Skip to main content
Tech.euFundingExplorerBeta

neuroClues

Our mission is to empower clinicians with Biomarkers allowing them to identify Neurological Disorders (Parkinson's Disease, Alzheimer's Disease and Multiple Sclerosis) years before visible symptoms.

neuroClues has raised €15M across 2 funding rounds from 6 investors, most recently a Series A round in Apr 2026. Based in Louvain-la-Neuve, Belgium; active in Healthtech. Data as of 28 Oct 2026.

Total raised
€15M
€14,999,998
Funding rounds
2
Investors
6
distinct backers
Active since
2024-04
latest 2026-04

Funding by year

EUR raised per year · 2026 YTD
neuroClues — funding by year — interactive chart.
Data table
neuroClues — funding by year
2024€5.0M
2026€10.0M

Signals

High confidence
Raise-next likelihood40
base rate 44% for Series A
  • ▼ Raised very recently
  • ▲ Up-round momentum
  • ▼ Low backer re-investment
Exit likelihood15
base rate 11% (2+ rounds)
  • ▼ Young (<3y)
  • ▲ Recently backed by strong-exit-track investors

Timing: too soon vs cohort gap · momentum up. Funding-only estimates, not predictions and not investment advice — see signals.

Funding rounds

2 rounds
DateStageAmountInvestors
2026-04-07Series A€10.0MEIC Fund,Existing investors,Olivier Legrain,TeamPact Ventures,White FundView deal →
2024-04-30Seed€5.0MEuropean Commission's EIC Accelerator program,White FundView deal →

Similar companies

same sector or country

Global coverage: FundingData